论文部分内容阅读
使用rHuEPO治疗慢性透析患者有明显的效果,但血压升高是其重要的合并症之一。对于使用rHuEPO治疗改善贫血期间的血液动力学指数的变化,尚无一致的看法,部分作者认为心脏输出增加,完全外周阻力减少;另外则认为外周阻力增高,血压无变化。基于上述原因,作者对12例慢性透析合并难治性贫血患者用rHuEPO治疗并对血流动力学变化因素进行了观察。 12例患者年龄为25～63岁(41±11),男性2例,女性10例,血透时间33～204月(80±47),全部为慢性肾小球肾炎终末期肾衰的患者。血液透析治疗开始后血压正常,(其中7例血透治疗前有高血压),所有患者均无充血性心力衰竭,未用抗高血压药物和心脏药物治疗。
The use of rHuEPO in patients with chronic dialysis has a significant effect, but elevated blood pressure is one of its important complications. There is no consensus on the use of rHuEPO to improve hemodynamic indices during anemia. Some authors believe that cardiac output is increased and complete peripheral resistance is reduced, while peripheral resistance is elevated and blood pressure is unchanged. For these reasons, the author of 12 patients with chronic dialysis and refractory anemia treated with rHuEPO and hemodynamic changes were observed. Twelve patients were aged 25-63 (41 ± 11), 2 males, 10 females, and hemodialysis time ranging from 33 to 204 months (80 ± 47), all of whom were patients with end-stage renal failure in chronic glomerulonephritis. Blood pressure was normal at the beginning of hemodialysis treatment (7 of the hemodialysis patients had high blood pressure before treatment). None of the patients had congestive heart failure and were not treated with antihypertensives and cardiac medications.